Tetsuya Koyama

EPS Holdings, Inc. engages in the drug development business. It operates through the following segments: Contract Research Organization (CRO), Site Management Organization (SMO), Contract Sales Organization (CSO), Global Research, Ekishin, and Others. The CRO segment offers clinical trials, data management, and statistical analysis. The SMO segment enters into contracts with medical institutions to conduct clinical trials. The CSO segment provides drug information and awareness for medical and pharmaceutical industries. The Global Research segment provides consignment services through its subsidiary for multilateral clinical trials in Asia-Pacific. The Ekishin segment focuses on medical equipment, pharmaceutical and investment related businesses through its Japan and China based subsidiaries. The Others segment provides various services related to management of clinical research from business processing outsource business related to medicine and medical care. The company was founded on May 30, 1991 and is headquartered in Tokyo, Japan.